AGA’s new clinical practice guideline on the pharmacological management of moderate-to-severe Crohn’s disease offers 16 evidence-based recommendations to guide treatment decisions.
This guideline incorporates the latest comparative research on 11 different medications, helping you determine the most effective therapies for your patients with moderate-to-severe Crohn’s disease.
Key updates
AGA recommends the use of infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab, or upadacitinib, and suggests the use of certolizumab pegol or vedolizumab for managing moderate-to-severe Crohn’s disease.
Notably, the guideline emphasizes early use of these advanced therapies — rather than step-up approaches that rely on corticosteroids or immunomodulators first — to improve long-term outcomes and reduce disease progression.